Epclusa and Dulcolax drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Epclusa (sofosbuvir; velpatasvir) and Dulcolax (bisacodyl). Common drug interactions include dysphagia among females and blood creatinine increased among males.
The phase IV clinical study analyzes what interactions people have when they take Epclusa and Dulcolax. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.
What is Epclusa?
Epclusa has active ingredients of sofosbuvir; velpatasvir. eHealthMe is studying from 12,120 Epclusa users. Check the latest studies of Epclusa.
What is Dulcolax?
Dulcolax has active ingredients of bisacodyl. It is often used in constipation. eHealthMe is studying from 12,897 Dulcolax users. Check the latest studies of Dulcolax.
13 people who take Epclusa and Dulcolax together, and have interactions are studied.
What are the common drug interactions of Epclusa and Dulcolax, by gender? *:
female:
- Dysphagia (a condition in which swallowing is difficult or painful)
- Nasopharyngitis (inflammation of the nasopharynx)
- Angioedema (rapid swelling of the dermis)
- Back pain
- Decreased appetite
- Diarrhoea
- Dry mouth
- Dyspepsia (indigestion)
- Dyspnoea (difficult or laboured respiration)
- Headache (pain in head)
male:
- Blood creatinine increased
- Confusional state
- Decreased appetite
- Headache (pain in head)
- Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
- Social avoidant behaviour (avoiding social connection a personality disorder)
What are the common drug interactions of Epclusa and Dulcolax, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Confusional state
- Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
- Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
- Blood creatinine increased
60+:
- Dysphonia (speech disorder attributable to a disorder of phonation)
- Hypersensitivity
- Swelling face
- Dysphagia (a condition in which swallowing is difficult or painful)
- Nasopharyngitis (inflammation of the nasopharynx)
- Angioedema (rapid swelling of the dermis)
- Back pain
- Fatigue (feeling of tiredness)
- Swollen tongue (swelling of tongue)
What are the existing conditions these people have? *
- Hepatitis C: 1 person, 7.69%
* Approximation only. Some reports may have incomplete information.
Do you take Epclusa and Dulcolax?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Epclusa and Dulcolax:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Epclusa:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Dulcolax:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Epclusa and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Dulcolax and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on sofosbuvir; velpatasvir and bisacodyl (the active ingredients of Epclusa and Dulcolax, respectively), and Epclusa and Dulcolax (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Cenestin and Restoril - now
- Lidocaine vs. Daypro, side effect and effectiveness comparison - 4 seconds ago
- Drug interactions of Novorapid and Potassium - 9 seconds ago
- Could Keytruda cause Upper Limb Fracture? - 22 seconds ago
- Drug interactions of Metolazone and Abilify - 29 seconds ago
- Could Yaz cause Nausea And Vomiting? - 32 seconds ago
- Could Revatio cause Sinus Disorder? - 34 seconds ago
- Could Rozerem cause Oedema? - 36 seconds ago
- Could Wellbutrin Sr cause Completed Suicide? - 39 seconds ago
- Drug interactions of Androgel and Benicar - 43 seconds ago